MA50582A - Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés - Google Patents

Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Info

Publication number
MA50582A
MA50582A MA050582A MA50582A MA50582A MA 50582 A MA50582 A MA 50582A MA 050582 A MA050582 A MA 050582A MA 50582 A MA50582 A MA 50582A MA 50582 A MA50582 A MA 50582A
Authority
MA
Morocco
Prior art keywords
symptoms
treatment
methods
protection against
associated conditions
Prior art date
Application number
MA050582A
Other languages
English (en)
Inventor
Jr Richard Thomas George
Chao-Yu Jin
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Publication of MA50582A publication Critical patent/MA50582A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050582A 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés MA50582A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582382P 2017-11-07 2017-11-07
US201862629900P 2018-02-13 2018-02-13

Publications (1)

Publication Number Publication Date
MA50582A true MA50582A (fr) 2020-09-16

Family

ID=66438309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050582A MA50582A (fr) 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Country Status (12)

Country Link
US (1) US20200261549A1 (fr)
EP (1) EP3706781A4 (fr)
JP (1) JP2021501793A (fr)
KR (1) KR20200085292A (fr)
CN (1) CN111601614A (fr)
AU (1) AU2018362603A1 (fr)
CA (1) CA3082070A1 (fr)
IL (1) IL274360A (fr)
MA (1) MA50582A (fr)
SG (1) SG11202003835PA (fr)
TW (1) TW201929894A (fr)
WO (1) WO2019092584A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871713B1 (fr) * 1995-11-09 2007-02-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose
WO2006069371A1 (fr) * 2004-12-22 2006-06-29 Baylor College Of Medicine Methode de lipidation plasmatique destinee a prevenir, a inhiber et/ou a inverser l'atherosclerose
MY159075A (en) * 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
EP2020603A1 (fr) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Procédé de stratification du risque chez des patients ayant une maladie associeé avec des coronaropathies
EP3192520B1 (fr) * 2009-07-29 2019-03-06 KAI Pharmaceuticals, Inc. Agents thérapeutiques de réduction des niveaux d'hormone parathyroïde
DK2566505T3 (da) * 2010-05-06 2020-01-20 Alphacore Pharma Llc Fremføring af kolesterylester til steroidogene væv
PL3178481T3 (pl) * 2010-06-30 2019-07-31 Csl Limited Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
US20150284471A1 (en) * 2011-12-08 2015-10-08 Amgen Inc Human LCAT Antigen Binding Proteins and Their Use in Therapy
RU2675824C2 (ru) * 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
US20170336420A1 (en) * 2014-11-04 2017-11-23 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for treating cardiovascular diseases

Also Published As

Publication number Publication date
IL274360A (en) 2020-06-30
SG11202003835PA (en) 2020-05-28
KR20200085292A (ko) 2020-07-14
JP2021501793A (ja) 2021-01-21
CN111601614A (zh) 2020-08-28
AU2018362603A1 (en) 2020-06-18
WO2019092584A1 (fr) 2019-05-16
EP3706781A4 (fr) 2021-07-21
EP3706781A1 (fr) 2020-09-16
TW201929894A (zh) 2019-08-01
CA3082070A1 (fr) 2019-05-16
US20200261549A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL284423A (en) Antisense oligonucleotides for the treatment of Pompe disease
MA43374A (fr) Méthodes de traitement de tumeurs malignes
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
HK1259031A1 (zh) 使用治療有效量的活化脂肪酸預防、治療和逆轉疾病
CL2016000820A1 (es) Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA42287A (fr) Traitement de patients atteints de diabète sucré de type 2
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MA43755A (fr) Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
MA50582A (fr) Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés
MA41782A (fr) Traitement de patients atteints de diabète de type 2
GB201515244D0 (en) Treatment of inflammatory disease or condition
MA45245A (fr) Méthode de traitement de maladie intestinale inflammatoire
PH12020550589A1 (en) Improved compound for treatment of heart failure
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
PL3137094T3 (pl) Leczenie i profilaktyka choroby alzheimera (ad)
MA50914A (fr) Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes
MA49754A (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
MA48477A (fr) Compositions et méthodes de traitement de la dépression
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
MA45177A (fr) Traitement de la maladie de parkinson
MA49358A (fr) Compositions et méthodes de traitement de tauopathies
IL263837A (en) Treatment of ocular disease
GB201610906D0 (en) Treatment of cardiovascular disease